Source: Eur Respir J, 54 (6) 1901522; 10.1183/13993003.01522-2019
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Sergey Borisov, Edvardas Danila, Andrei Maryandyshev, Margareth Dalcolmo, Skaidrius Miliauskas, Liga Kuksa, Selene Manga, Alena Skrahina, Saulius Diktanas, Luigi Ruffo Codecasa, Alena Aleksa, Judith Bruchfeld, Antoniya Koleva, Alberto Piubello, Zarir Farokh Udwadia, Onno W. Akkerman, Evgeny Belilovski, Enrique Bernal, Martin J. Boeree, Julen Cadiñanos Loidi, Qingshan Cai, Jose Joaquín Cebrian Gallardo, Masoud Dara, Edita Davidaviciene, Lina Davies Forsman, Jorge De Los Rios, Justin Denholm, Jacinta Drakšiene, Raquel Duarte, Seifeldin Eltaeb Elamin, Nadia Escobar Salinas, Maurizio Ferrarese, Alexey Filippov, Ana Garcia, José-María García-García, Ieva Gaudiesiute, Blagovesta Gavazova, Regina Gayoso, Roscio Gomez Rosso, Vygantas Gruslys, Gina Gualano, Wouter Hoefsloot, Jerker Jonsson, Elena Khimova, Heinke Kunst, Rafael Laniado-Laborín, Yang Li, Cecile Magis-Escurra, Vinicio Manfrin, Valentina Marchese, Elena Martínez Robles, Alberto Matteelli, Jesica Mazza-Stalder, Charalampos Moschos, Marcela Muñoz-Torrico, Hamdan Mustafa Hamdan, Birute Nakceriene, Laurent Nicod, Magnolia Nieto Marcos, Domingo Juan Palmero, Fabrizio Palmieri, Apostolos Papavasileiou, Marie-Christine Payen, Agostina Pontarelli, Sarai Quirós, Adrian Rendon, Laura Saderi, Agnese Šmite, Ivan Solovic, Mahamadou Bassirou Souleymane, Marina Tadolini, Martin van den Boom, Marisa Vescovo, Pietro Viggiani, Askar Yedilbayev, Rolandas Zablockis, Dmitry Zhurkin, Matteo Zignol, Dina Visca, Antonio Spanevello, José A. Caminero, Jan-Willem Alffenaar, Simon Tiberi, Rosella Centis, Lia D'Ambrosio, Emanuele Pontali, Giovanni Sotgiu, Giovanni Battista Migliori. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur Respir J, 54 (6) 1901522; 10.1183/13993003.01522-2019

Member's Comments

No comment yet.

Related content which might interest you: Adverse events in the treatment of multidrug-resistant tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Spectrum of adverse drug reactions during MDR TB treatment Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Treatment of latent tuberculosis infection: completion rates and adverse effects Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003 Risk of serious adverse reactions during the treatment of new tuberculosis patients Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012 Adverse events during treatment for latent tuberculosis infection Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Adverse effects of MDR-TB treatment with a standardized regimen: A report from Iran Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010 Prevention and mechanism of undesirable adverse reactions in patients with pulmonary tuberculosis with extensive drug-resistance (XDR) combined with type 2 diabetes Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019 Could side effects of MDR-TB treatment change the outcome of the disease? Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Treatment interruptions in patients with MDR/XDR-TB: risk factors and impact on treatment outcomes Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 The global risk of dying from multidrug-resistant tuberculosis (MDR-TB) Source: International Congress 2014 – Tuberculosis epidemiology: novel features Year: 2014 Risk factors for acquired drug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Adverse drug reactions to second line anti tuberculosis drugs: A prospective study in Mumbai, India Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 The global response to rifampicin-resistant tuberculosis: Current situation and recent trends Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Risk factors for tuberculosis relapse in Polish patients Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Adverse reactions during treatment of multidrug-resistant and extensively drug-resistant tuberculosis Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 Latent tuberculosis infection prevalence and risk of developing active TB among patients eligible for starting anti-TNFα therapy Source: International Congress 2015 – Screening strategies in TB Year: 2015 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Outcomes of directly observed treatment for drug resistant tuberculosis Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016